Sana Biotechnology, Inc. (NASDAQ:SANA) Shares Bought by Fmr LLC

FMR LLC lifted its stake in Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) by 16.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 31,609,175 shares of the company's stock after purchasing an additional 4,438,949 shares during the quarter. FMR LLC owned about 14.16% of Sana Biotechnology worth $131,494,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Sana Biotechnology by 20.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company's stock valued at $163,000 after purchasing an additional 5,090 shares during the last quarter. Arizona State Retirement System raised its position in Sana Biotechnology by 36.7% during the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company's stock worth $202,000 after buying an additional 9,940 shares during the last quarter. Blue Trust Inc. raised its position in Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company's stock worth $55,000 after buying an additional 12,154 shares during the last quarter. Algert Global LLC purchased a new position in Sana Biotechnology during the 2nd quarter worth approximately $73,000. Finally, Dark Forest Capital Management LP raised its position in Sana Biotechnology by 112.0% during the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company's stock worth $149,000 after buying an additional 14,430 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of Sana Biotechnology stock in a transaction on Tuesday, September 24th. The shares were sold at an average price of $4.08, for a total value of $612,000.00. Following the sale, the director now owns 2,848,121 shares of the company's stock, valued at approximately $11,620,333.68. This trade represents a 5.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 31.10% of the stock is owned by corporate insiders.

Sana Biotechnology Stock Up 1.6 %

Shares of NASDAQ:SANA traded up $0.04 during trading on Wednesday, hitting $2.61. 1,745,036 shares of the stock traded hands, compared to its average volume of 2,130,221. The company has a market cap of $582.73 million, a price-to-earnings ratio of -1.85 and a beta of 1.33. The company has a fifty day moving average price of $3.45 and a two-hundred day moving average price of $5.00. Sana Biotechnology, Inc. has a 52-week low of $2.29 and a 52-week high of $12.00.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. On average, equities research analysts predict that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Citigroup raised their price target on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. HC Wainwright reissued a "buy" rating and set a $8.00 price target on shares of Sana Biotechnology in a research report on Wednesday, November 27th. Finally, JMP Securities lowered shares of Sana Biotechnology from an "outperform" rating to a "market perform" rating in a research report on Tuesday, November 5th.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.